At #SABCS24 @danafarber.bsky.social’s @elmayermd.bsky.social is sharing initial findings from phase 2 trial of neoadjuvant niraparib + dostarlimab. The PARPi/anti-PD1 combo showed encouraging results in patients with HR+ bc & an inherited increased risk of bc, including an 18.8 percent pCR rate.